ERBB2 and breast cancer: Anders et al. (2020) emphasized the significance of targeted therapies in breast oncology, noting that while CDK4/6 inhibitors are effective for HR+/HER2- breast cancer, they may cause adverse effects affecting multiple systems, including the dermatological events observed in this case [17].